MARKET

REVB

REVB

Revelation Biosciences
NASDAQ
3.178
+0.083
+2.67%
Closed 19:42 05/09 EDT
OPEN
3.040
PREV CLOSE
3.095
HIGH
3.214
LOW
3.040
VOLUME
31.62K
TURNOVER
18.12K
52 WEEK HIGH
60.80
52 WEEK LOW
2.360
MARKET CAP
3.06M
P/E (TTM)
-0.0362
1D
5D
1M
3M
1Y
5Y
1D
Revelation Biosciences GAAP EPS of -$2.11
Seeking Alpha · 3d ago
Revelation Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 3d ago
Press Release: Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
Dow Jones · 3d ago
Press Release: Revelation Biosciences, Inc. -2-
Dow Jones · 3d ago
Revelation Biosciences Inc <REVB.OQ> expected to post a loss of $6.88 a share - Earnings Preview
Reuters · 5d ago
Weekly Report: what happened at REVB last week (0428-0502)?
Weekly Report · 6d ago
Weekly Report: what happened at REVB last week (0421-0425)?
Weekly Report · 04/28 11:37
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/23 17:05
More
About REVB
Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).

Webull offers Revelation Biosciences Inc stock information, including NASDAQ: REVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REVB stock methods without spending real money on the virtual paper trading platform.